News Detail

Plus Therapeutics Announces Data From ReSPECT-LM Phase 1 Single Dose Escalation Trial Presented At The SNO/ASCo CNS Metastases Conference, Showing Reyobiq Is Feasible, With Manageable Safety Profile, And Shows Efficacy Signal For Leptomeningeal Metastases Patients

Benzinga · 08/18 11:32

Listen to the news

Presented Data Highlights:

Radiographic and clinical response rate of 76% and 87%, respectively, through day 112
CSF tumor cell enumeration (TCE) assays (CNSide test) showed a maximum reduction over baseline of 100% at day 28
Five of the 7 patients with a TCE response >80% survived at least 1 year
RNA sequencing of LM cells showed early induction of apoptosis, with an innate immune response followed by an adaptive immune response by day 28
Median overall survival of 9 months across cohorts 1-4 (20 patients) months, comparing favorably with literature reports of ~4 months
No dose-limiting toxicity (DLT) was observed in cohorts 1-4, with 1 DLT in each of cohorts 5 and 6 of grade 4 cytopenia
The majority of adverse events across the trial were Grade 1 and 2
Mean absorbed dose to the cranial and spinal subarachnoid space was 272 Gy in cohort 6
A recommended phase 2 single dose of 44.1 mCi was determined

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.